6 stories mentioning DOCUpdated 8d ago
Every FINWIRES story that references DOC, newest first.
Healthpeak Properties (DOC) has an average rating of overweight and mean price target of $20.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $20.75, Change: $+0.28, Percent Change: +1.37%
Healthpeak Properties (DOC) has an average rating of overweight and mean price target of $19.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $19.45, Change: $-0.32, Percent Change: -1.62%
Healthpeak Properties (DOC) has an average rating of overweight and mean price target of $19.41, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $2 to $21, reflecting a forward P/FFO of 12.0x our 2026 FFO estimate, a discount to DOC's three-year forward average (10.6x) as headwinds in Lab are likely to continue in 2026 mixed with capital recycling plans early in the year. We lower our 2026 FFO view by $0.02 to $1.75 and increase 2027's by $0.02 to $1.82. DOC successfully executed the IPO of Janus Living, which now trades at a premium multiple relative to DOC. We believe this will accelerate JAN's acquisition ability in the senior housing market. The most surprising note from management was that it sees the lab space likely to grow occupancy by the end of 2026. This is strong outperformance relative to the largest lab focused operator Alexandria Real Estate Equities, with DOC guiding for a 100-bp improvement this year. Boston continues to be the market with the largest oversupply of lab space, but the West Cambridge location specifically is seeing strong demand currently.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DOC delivered mixed Q1 2026 results with revenue up 7.1% Y/Y to $753M and rental revenue of $739M (+7.5%) exceeding consensus by $46M, though FFO per share declined to $0.45 from $0.46 but beat estimates by $0.02. The successful Janus Living IPO generated $880M in proceeds and created a $6.9B market cap senior housing platform, validating management's value unlock strategy while DOC retains 81.6% ownership. Updated 2026 guidance reflects the IPO impact, with EPS raised to $0.46-$0.50 while FFO lowered to $1.68-$1.72 due to lost management fees. Same-store NOI was flat with Senior Housing strength (+13.8%) offset by Lab struggles (-7.2%). Occupancy pressures continued with Lab down 740 bps Y/Y to 90.4% and Outpatient Medical down 70 bps to 91.8%. DOC repurchased $100M in shares. We believe Outpatient Medical occupancy will improve but see Lab vacancy rates increasing through Q3 2026. We see persistent biotech funding challenges limiting Lab upside through 1H 2027.
Healthpeak Properties (DOC) has an average rating of overweight and mean price target of $19.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
